← Back to Clinical Trials
Recruiting NCT06587906

NCT06587906 Postoperative Complications Following Skull Base Tumor Resection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06587906
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Skull Base Tumor
Study Type OBSERVATIONAL
Enrollment 122 participants
Start Date 2024-09-10
Primary Completion 2027-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Pulmonary ultrasound examination

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 122 participants in total. It began in 2024-09-10 with a primary completion date of 2027-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The skull base tumor is located in the deep intracranial layer and is closely related to the brain stem and intracranial nerves. The incidence of postoperative complications after skull base tumor resection is high. Therefore, the perioperative management of skull base tumor resection is challenging.

Eligibility Criteria

Inclusion Criteria: * Age 18 and above * American Society of Anesthesiologists physical status I to III * Undergoing elective resection of skull base tumors * Obtaining written informed consent Exclusion Criteria: * Heart failure, myocarditis, pericarditis, and cardiomyopathy * Myocardial ischemia less than 6 months old * Severe arrhythmia * Severe bradycardia (heart rate below 50 beats per minute) * Unable to complete preoperative cardiac assessment * Severe liver dysfunction (Child Pugh C-grade) * Severe lung diseases

Contact & Investigator

Central Contact

Yuming Peng

✉ florapym766@163.com

📞 18601076588

Principal Investigator

Yuming Peng

STUDY CHAIR

Beijing Tiantan Hospital

Frequently Asked Questions

Who can join the NCT06587906 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Skull Base Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06587906 currently recruiting?

Yes, NCT06587906 is actively recruiting participants. Contact the research team at florapym766@163.com for enrollment information.

Where is the NCT06587906 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06587906 clinical trial?

NCT06587906 is sponsored by Beijing Tiantan Hospital. The principal investigator is Yuming Peng at Beijing Tiantan Hospital. The trial plans to enroll 122 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology